Annual EBIT
-$110.66 M
+$1.47 M+1.31%
December 31, 2023
Summary
- As of February 12, 2025, FULC annual earnings before interest & taxes is -$110.66 million, with the most recent change of +$1.47 million (+1.31%) on December 31, 2023.
- During the last 3 years, FULC annual EBIT has fallen by -$39.05 million (-54.53%).
- FULC annual EBIT is now -381.29% below its all-time high of -$22.99 million, reached on December 31, 2017.
Performance
FULC EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$23.06 M
-$75.56 M-143.94%
September 30, 2024
Summary
- As of February 12, 2025, FULC quarterly earnings before interest & taxes is -$23.06 million, with the most recent change of -$75.56 million (-143.94%) on September 30, 2024.
- Over the past year, FULC quarterly EBIT has increased by +$4.93 million (+17.61%).
- FULC quarterly EBIT is now -143.94% below its all-time high of $52.49 million, reached on June 30, 2024.
Performance
FULC Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$28.40 M
+$4.38 M+13.36%
September 30, 2024
Summary
- As of February 12, 2025, FULC TTM earnings before interest & taxes is -$28.40 million, with the most recent change of +$4.38 million (+13.36%) on September 30, 2024.
- Over the past year, FULC TTM EBIT has increased by +$82.27 million (+74.34%).
- FULC TTM EBIT is now -288.47% below its all-time high of -$7.31 million, reached on March 31, 2018.
Performance
FULC TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
FULC EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1.3% | +17.6% | +74.3% |
| 3 y3 years | -54.5% | +17.6% | +74.3% |
| 5 y5 years | -230.4% | +17.6% | +74.3% |
FULC EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -36.5% | +1.3% | -143.9% | +32.6% | at high | +75.1% |
| 5 y | 5-year | -54.5% | +1.3% | -143.9% | +32.6% | at high | +75.1% |
| alltime | all time | -381.3% | +1.3% | -143.9% | +38.0% | -288.5% | +75.1% |
Fulcrum Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$23.06 M(-143.9%) | -$28.40 M(-13.4%) |
| Jun 2024 | - | $52.49 M(-275.9%) | -$32.77 M(-70.9%) |
| Mar 2024 | - | -$29.83 M(+6.6%) | -$112.56 M(+1.7%) |
| Dec 2023 | -$110.66 M(-1.3%) | -$27.99 M(+2.0%) | -$110.66 M(-0.0%) |
| Sep 2023 | - | -$27.44 M(+0.5%) | -$110.68 M(+3.3%) |
| Jun 2023 | - | -$27.29 M(-2.3%) | -$107.13 M(-6.1%) |
| Mar 2023 | - | -$27.94 M(-0.3%) | -$114.08 M(+1.7%) |
| Dec 2022 | -$112.13 M(+38.3%) | -$28.01 M(+17.2%) | -$112.13 M(+4.1%) |
| Sep 2022 | - | -$23.89 M(-30.2%) | -$107.68 M(+3.0%) |
| Jun 2022 | - | -$34.23 M(+31.7%) | -$104.56 M(+16.2%) |
| Mar 2022 | - | -$26.00 M(+10.4%) | -$90.01 M(+11.0%) |
| Dec 2021 | -$81.05 M | -$23.56 M(+13.4%) | -$81.05 M(+7.7%) |
| Sep 2021 | - | -$20.77 M(+5.5%) | -$75.28 M(+2.3%) |
| Jun 2021 | - | -$19.68 M(+15.5%) | -$73.62 M(+5.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$17.04 M(-4.2%) | -$69.86 M(-2.4%) |
| Dec 2020 | -$71.61 M(-15.0%) | -$17.79 M(-6.9%) | -$71.61 M(+1.8%) |
| Sep 2020 | - | -$19.10 M(+20.0%) | -$70.31 M(+3.1%) |
| Jun 2020 | - | -$15.92 M(-15.3%) | -$68.22 M(+3.7%) |
| Mar 2020 | - | -$18.80 M(+14.0%) | -$65.79 M(-21.9%) |
| Dec 2019 | -$84.22 M(+151.4%) | -$16.49 M(-3.0%) | -$84.22 M(+9.4%) |
| Sep 2019 | - | -$17.01 M(+26.0%) | -$76.98 M(+11.5%) |
| Jun 2019 | - | -$13.49 M(-63.8%) | -$69.06 M(+8.9%) |
| Mar 2019 | - | -$37.23 M(+302.4%) | -$63.41 M(+89.3%) |
| Dec 2018 | -$33.50 M(+45.7%) | -$9.25 M(+1.8%) | -$33.50 M(+38.2%) |
| Sep 2018 | - | -$9.09 M(+15.8%) | -$24.25 M(+60.0%) |
| Jun 2018 | - | -$7.85 M(+7.4%) | -$15.16 M(+107.4%) |
| Mar 2018 | - | -$7.31 M | -$7.31 M |
| Dec 2017 | -$22.99 M | - | - |
FAQ
- What is Fulcrum Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics annual EBIT year-on-year change?
- What is Fulcrum Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics quarterly EBIT year-on-year change?
- What is Fulcrum Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Fulcrum Therapeutics?
- What is Fulcrum Therapeutics TTM EBIT year-on-year change?
What is Fulcrum Therapeutics annual earnings before interest & taxes?
The current annual EBIT of FULC is -$110.66 M
What is the all time high annual EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high annual earnings before interest & taxes is -$22.99 M
What is Fulcrum Therapeutics annual EBIT year-on-year change?
Over the past year, FULC annual earnings before interest & taxes has changed by +$1.47 M (+1.31%)
What is Fulcrum Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of FULC is -$23.06 M
What is the all time high quarterly EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high quarterly earnings before interest & taxes is $52.49 M
What is Fulcrum Therapeutics quarterly EBIT year-on-year change?
Over the past year, FULC quarterly earnings before interest & taxes has changed by +$4.93 M (+17.61%)
What is Fulcrum Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of FULC is -$28.40 M
What is the all time high TTM EBIT for Fulcrum Therapeutics?
Fulcrum Therapeutics all-time high TTM earnings before interest & taxes is -$7.31 M
What is Fulcrum Therapeutics TTM EBIT year-on-year change?
Over the past year, FULC TTM earnings before interest & taxes has changed by +$82.27 M (+74.34%)